A. Jenner

Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer

Patrick Schöffski, B. Thate, Gernot Beutel et al. · Annals of Oncology · 2004 · 66 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +6

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment

Lot A. Devriese, Petronella O. Witteveen, Silvia Marchetti et al. · Cancer Chemotherapy and Pharmacology · 2012 · 50 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Chris Parker, Noel W. Clarke, Adrian Cook et al. · The Lancet · 2024 · 49 citations · Full text

Medicine, Oncology, Surgery +15

Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole

Lot A. Devriese, Marja Mergui‐Roelvink, J. Wanders et al. · Investigational New Drugs · 2012 · 34 citations

Medicine, Pharmacokinetics, Pharmacology +4

Results of the Screening program for congenital hypothyroidism in Berlin (1978–1995)

Annette Grüters, Klaus‐Peter Liesenkötter, M. Zapico et al. · Experimental and Clinical Endocrinology & Diabetes · 2009 · 33 citations

Medicine, Endocrinology, Pediatrics +17